drugset / Trial / NCT05489406
Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.
RandomizedCrossoverOpen-labelOther
Summary
This relative bioavailability (RBA) study will be conducted to investigate whether there is a potential pharmacokinetic effect when paediatric DTG and F/TAF are taken together as dispersible formulations. This study will be performed in healthy volunteers instead of HIV-infected patients.
Timeline
- Start
- 2022-10-06
- Primary completion
- 2023-03-24
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 30 mg | Oral |
| Subject | emtricitabine | Other / unclassified | 180 mg | Oral |
| Subject | tenofovir alafenamide | Small molecule | 22.5 mg | Oral |